Is Hepion Pharmaceuticals, Inc. HEPA stock halal to invest in?

No, as of February 2026, Hepion Pharmaceuticals, Inc. stock (HEPA) is currently categorized as NOT Shariah Compliant. The company's status is determined by a rigorous financial screening process, which uses the criteria set by the AAOIFI (Accounting and Auditing Organization for Islamic Financial Institutions) as the primary global standard for Islamic investing. Hepion Pharmaceuticals, Inc. has been assessed to have exceeded the permissible financial thresholds—specifically in areas like interest-bearing debt or non-permissible income (such as income from interest)—and, therefore, does not qualify as a halal investment under the current review. For investors seeking Shariah compliant global stocks, it is essential to check the latest compliance status, as these screenings are updated regularly (e.g., monthly) or upon the release of new financial reports. You can find the most current status for Hepion Pharmaceuticals, Inc. and alternative halal stock options within the Tabadulat app.

How often is Hepion Pharmaceuticals, Inc. HEPA reviewed for Shariah compliance?

At Tabadulat, we receive Shariah compliance data on Hepion Pharmaceuticals, Inc. HEPA monthly. We apply the rigorous AAOIFI screening methodology under the direct supervision of our dedicated Shariah Supervisory Board to ensure your investments are consistently compliant.

Does Hepion Pharmaceuticals, Inc. HEPA pass the AAOIFI Non Permissible Income criteria?

No, as of February 2026, Hepion Pharmaceuticals, Inc. stock (HEPA) does not pass the AAOIFI Non Permissible Income criterion. The company's income from non-permissible sources has exceeded the permissible threshold set by AAOIFI, indicating the stock is currently not Shariah compliant for this screen.

Does Hepion Pharmaceuticals, Inc. HEPA pass the AAOIFI Interest Bearing Investments criteria?

No, as of February 2026, Hepion Pharmaceuticals, Inc. stock (HEPA) does not pass the AAOIFI Interest Bearing Investments criterion. The company's interest-bearing investments have exceeded the permissible threshold set by AAOIFI, indicating the stock is currently not Shariah compliant for this screen.

Does STOCK pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of February 2026, Hepion Pharmaceuticals, Inc. stock (HEPA) passes the AAOIFI Interest Bearing Debt criterion. The company's interest-bearing debt is below the acceptable threshold set by AAOIFI.

English

العربية

Be the First to Know!

Join our waitlist for exclusive early access to Tabadulat’s Shariah-compliant trading platform. Get notified as soon as we go live and start investing with confidence.

Hepion Pharmaceuticals, Inc.

NASDAQ

Shariah-Compliant

Not Shariah

HEPA

About

Hepion Pharmaceuticals, Inc.

HEPA

Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapies for chronic liver diseases. Its key asset, Rencofilstat, is a potent cyclophilin inhibitor aimed at treating conditions such as non-alcoholic steatohepatitis (NASH), liver fibrosis, and hepatocellular carcinoma (HCC). Rencofilstat targets multiple molecular pathways involved in liver disease progression, from initial triggers to those impairing liver function. The company leverages its AI-POWR platform for integrative bioinformatic analysis, utilizing both proprietary clinical data and public multi-omic databases to inform drug development. Recently, Hepion has transitioned towards developing and licensing diagnostic tests for diseases including celiac disease, respiratory infections, Helicobacter pylori, and HCC. Incorporated in 2013 and headquartered in Morristown, New Jersey, Hepion holds FDA Fast Track and Orphan Drug designations for Rencofilstat, reflecting its significance in addressing unmet medical needs in liver disease therapeutics.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

Website:

https://hepionpharma.com

HEPA

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Sign Up.

Begin by creating your Tabadulat account. Simply enter your details and complete the verification process. You’ll be up and running in no time.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.

Step 4

Trade.

Once you’ve chosen the right stocks, simply place your trades. Our platform offers real-time market data and seamless execution.

Mobile screen showing investment portfolio with $100,000 total value, $48,000 invested, and a $2,000 return (4.50%) with a line graph and options for 1W, 1M, 3M, YTD, 1Y, Max, plus Trade and Deposit buttons.

Step 5

Track.

Track your Portfolio and monitor your investments with our easy-to-use dashboard. View your portfolio performance, manage assets, and make adjustments as needed.

Step 6

Withdraw.

When you're ready, withdraw your funds quickly and securely to your bank account.

Hepion Pharmaceuticals, Inc.

About

Hepion Pharmaceuticals, Inc.

HEPA

Frequently asked questions

Is Hepion Pharmaceuticals, Inc. HEPA stock halal to invest in?

How often is Hepion Pharmaceuticals, Inc. HEPA reviewed for Shariah compliance?

Does Hepion Pharmaceuticals, Inc. HEPA pass the AAOIFI Non Permissible Income criteria?

Does Hepion Pharmaceuticals, Inc. HEPA pass the AAOIFI Interest Bearing Investments criteria?

Does STOCK pass the AAOIFI Interest Bearing Debt criteria?

How do I buy Hepion Pharmaceuticals, Inc. HEPA stock?

Sign Up.

Deposit.

Screen.

Trade.

Track.

Withdraw.